PL378025A1 - Pochodne bifenylowe - Google Patents

Pochodne bifenylowe

Info

Publication number: PL378025A1
Authority: PL; Poland
Prior art keywords: biphenyl derivatives; biphenyl; derivatives
Prior art date: 2003-02-14

Application number

PL378025A

Other languages

English (en)

Other versions

PL216397B1 (pl

Inventor

Mathai Mammen

Sarah Dunham

Adam Hughes

Tae Weon Lee

Craig Husfeld

Eric Stangeland

Yan Chen

Original Assignee

Theravance, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-14

Filing date

2004-02-13

Publication date

2006-02-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32912274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL378025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-13 Application filed by Theravance, Inc. filed Critical Theravance, Inc.

2006-02-20 Publication of PL378025A1 publication Critical patent/PL378025A1/pl

2014-03-31 Publication of PL216397B1 publication Critical patent/PL216397B1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9433—(Nor)adrenaline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL378025A 2003-02-14 2004-02-13 Ester 1-[2-(2-chloro-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrochinolin-5-ylo)etyloamino]metylo}-5-metoksyfenylokarbamoilo)etylo]piperydyn-4-ylowy kwasu bifenyl-2-ylokarbamowego, zawierająca go kompozycja farmaceutyczna oraz jego zastosowania w medycynie PL216397B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44784303P	2003-02-14	2003-02-14
US46703503P	2003-05-01	2003-05-01

Publications (2)

Publication Number	Publication Date
PL378025A1 true PL378025A1 (pl)	2006-02-20
PL216397B1 PL216397B1 (pl)	2014-03-31

Family

ID=32912274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL378025A PL216397B1 (pl)	2003-02-14	2004-02-13	Ester 1-[2-(2-chloro-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrochinolin-5-ylo)etyloamino]metylo}-5-metoksyfenylokarbamoilo)etylo]piperydyn-4-ylowy kwasu bifenyl-2-ylokarbamowego, zawierająca go kompozycja farmaceutyczna oraz jego zastosowania w medycynie

Country Status (28)

Country	Link
US (15)	US7141671B2 (pl)
EP (5)	EP3012254B1 (pl)
JP (6)	JP4555283B2 (pl)
KR (3)	KR101223991B1 (pl)
AR (1)	AR043176A1 (pl)
AT (1)	ATE482934T1 (pl)
AU (2)	AU2004213411B2 (pl)
BR (1)	BRPI0407508B8 (pl)
CA (1)	CA2515777C (pl)
CY (2)	CY1111276T1 (pl)
DE (1)	DE602004029347D1 (pl)
DK (2)	DK1615889T3 (pl)
ES (2)	ES2566155T3 (pl)
HK (1)	HK1216892A1 (pl)
HU (1)	HUE027380T2 (pl)
IL (1)	IL169922A (pl)
IS (1)	IS2847B (pl)
MX (1)	MXPA05008528A (pl)
MY (1)	MY148487A (pl)
NO (2)	NO331947B1 (pl)
NZ (1)	NZ541579A (pl)
PE (1)	PE20040950A1 (pl)
PL (1)	PL216397B1 (pl)
PT (1)	PT1615889E (pl)
RU (1)	RU2330841C2 (pl)
SI (2)	SI1615889T1 (pl)
TW (1)	TWI331995B (pl)
WO (3)	WO2004074812A2 (pl)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6693202B1 (en) *	1999-02-16	2004-02-17	Theravance, Inc.	Muscarinic receptor antagonists
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PE20050130A1 (es) *	2002-08-09	2005-03-29	Novartis Ag	Compuestos organicos
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) *	2003-04-01	2004-10-21	Theravance, Inc.	Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) *	2003-05-28	2009-07-15	Theravance Inc	Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
US7872052B2 (en) *	2003-06-06	2011-01-18	Arexis Ab	Use of heterocyclic compounds as SCCE inhibitors
US20050026948A1 (en) *	2003-07-29	2005-02-03	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2329586T3 (es) *	2003-11-21	2009-11-27	Theravance, Inc.	Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
TW200531692A (en)	2004-01-12	2005-10-01	Theravance Inc	Aryl aniline derivatives as β2 adrenergic receptor agonists
WO2005080375A1 (en) *	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
US7262205B2 (en) *	2004-03-11	2007-08-28	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) *	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) *	2004-03-11	2005-09-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) *	2004-03-11	2005-12-01	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
EP1723109A1 (en) *	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en)	2004-03-11	2005-09-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) *	2004-03-11	2007-10-11	セラヴァンス，インコーポレーテッド	ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
EP1723110A1 (en) *	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
NZ551669A (en) *	2004-05-31	2010-07-30	Almirall Lab	Combinations comprising antimuscarinic agents and PDE4 inhibitors
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
TWI374883B (en)	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
WO2006023457A1 (en) *	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en)	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
WO2006050239A2 (en) *	2004-10-29	2006-05-11	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
TW200714587A (en) *	2005-03-10	2007-04-16	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en)	2005-03-10	2010-02-09	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
US7629336B2 (en) *	2005-03-10	2009-12-08	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) *	2005-03-10	2008-10-02	セラヴァンス，インコーポレーテッド	ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
EP1866284A1 (en)	2005-03-10	2007-12-19	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US7728144B2 (en) *	2005-06-13	2010-06-01	Theravance, Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US8429052B2 (en) *	2005-07-19	2013-04-23	Lincoln National Life Insurance Company	Method and system for providing employer-sponsored retirement plan
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
EP1924553A1 (en)	2005-08-08	2008-05-28	Argenta Discovery Limited	Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
TW200738658A (en)	2005-08-09	2007-10-16	Astrazeneca Ab	Novel compounds
US7910708B2 (en)	2005-10-21	2011-03-22	Novartis Ag	Anti-IL13 human antibodies
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
US7973055B2 (en) *	2006-03-09	2011-07-05	Theravance, Inc.	Crystalline forms of a biphenyl compound
TW200745067A (en)	2006-03-14	2007-12-16	Astrazeneca Ab	Novel compounds
MX2008011963A (es)	2006-03-20	2008-10-01	Pfizer Ltd	Derivados de amina.
ATE549337T1 (de)	2006-04-21	2012-03-15	Novartis Ag	Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2296516B1 (es) *	2006-04-27	2009-04-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
GB0613154D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
BRPI0719270A2 (pt) *	2006-10-04	2014-03-11	Pfizer Ltd	Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
ES2302447B1 (es) *	2006-10-20	2009-06-12	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en)	2006-12-20	2008-08-16	Astrazeneca Ab	Novel compounds 569
RS51644B (sr)	2007-01-10	2011-10-31	Irm Llc.	Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
JP4720909B2 (ja) *	2007-01-31	2011-07-13	東レ株式会社	ベンジルアミン誘導体またはその薬学的に許容される酸付加塩、およびその医薬用途
GB0702458D0 (en)	2007-02-08	2007-03-21	Astrazeneca Ab	Salts 668
ES2306595B1 (es)	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US8682466B2 (en) *	2007-05-04	2014-03-25	Taiwan Semiconductor Manufacturing Company, Ltd.	Automatic virtual metrology for semiconductor wafer result prediction
KR20100005730A (ko)	2007-05-07	2010-01-15	노파르티스 아게	유기 화합물
ES2320961B1 (es) *	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EA017919B1 (ru)	2007-12-10	2013-04-30	Новартис Аг	Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
EP2231642B1 (en)	2008-01-11	2013-10-23	Novartis AG	Pyrimidines as kinase inhibitors
KR101273200B1 (ko) *	2008-02-06	2013-06-17	펄마젠 쎄라퓨틱스 (시너지) 리미티드	화합물
EP2096105A1 (en) *	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20110040818A (ko)	2008-06-10	2011-04-20	노파르티스 아게	상피 나트륨 채널 차단제로서의 피라진 유도체
WO2009154557A1 (en)	2008-06-18	2009-12-23	Astrazeneca Ab	Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8263623B2 (en) *	2008-07-11	2012-09-11	Pfizer Inc.	Triazol derivatives useful for the treatment of diseases
WO2010007561A1 (en) *	2008-07-15	2010-01-21	Pfizer Limited	Novel compounds active as muscarinic receptor antagonists
EP2328868A1 (en) *	2008-07-15	2011-06-08	Pfizer Limited	Novel compounds active as muscarinic receptor antagonists
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
TW201036957A (en)	2009-02-20	2010-10-16	Astrazeneca Ab	Novel salt 628
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
CA2755697A1 (en)	2009-03-17	2010-09-23	Daiichi Sankyo Company, Limited	Amide derivative
CA2758353C (en) *	2009-04-14	2017-06-06	Dean David Edney	Process for the preparation of a biphenyl-2-ylcarbamic acid ester
AU2015234331B2 (en) *	2009-04-23	2017-08-03	Theravance Biopharma R&D Ip, Llc	Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PT2599778T (pt) *	2009-04-23	2017-06-06	Theravance Respiratory Co Llc	Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
WO2010126025A1 (ja) *	2009-04-30	2010-11-04	帝人ファーマ株式会社	四級アンモニウム塩化合物
EP2813227A1 (en)	2009-10-22	2014-12-17	Vertex Pharmaceuticals Incorporated	Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011081937A1 (en)	2009-12-15	2011-07-07	Gilead Sciences, Inc.	Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
JP5959117B2 (ja) *	2010-07-13	2016-08-02	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ビフェニル−２−イルカルバミン酸を調製するためのプロセス
RS55856B1 (sr)	2010-07-14	2017-08-31	Novartis Ag	Heterociklična jedinjenja agonisti ip receptora
WO2012032546A2 (en) *	2010-09-08	2012-03-15	Cadila Healthcare Limited	Process for the preparation of salmeterol and its intermediates
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
AR083115A1 (es) *	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
GB201016912D0 (en)	2010-10-07	2010-11-24	Astrazeneca Ab	Novel combination
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP6060242B2 (ja) *	2010-11-30	2017-01-11	株式会社日立国際電気	基板処理装置、半導体装置の製造方法及びバッフル構造
AU2012220572A1 (en)	2011-02-25	2013-08-29	Irm Llc	Compounds and compositions as trk inhibitors
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
RU2606121C2 (ru) *	2011-06-10	2017-01-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
HRP20151317T1 (hr)	2011-06-10	2016-01-01	Chiesi Farmaceutici S.P.A.	Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
WO2013038386A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
EP2578570A1 (en)	2011-10-07	2013-04-10	Almirall, S.A.	Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2561353T3 (es)	2012-01-13	2016-02-25	Novartis Ag	Sales de un agonista del receptor IP
EP2802581A1 (en)	2012-01-13	2014-11-19	Novartis AG	7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
CN104053659B (zh)	2012-01-13	2016-11-09	诺华股份有限公司	用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
WO2013105063A1 (en)	2012-01-13	2013-07-18	Novartis Ag	Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en)	2012-01-13	2014-11-19	Novartis AG	Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US20140357641A1 (en)	2012-01-13	2014-12-04	Novartis Ag	IP receptor agonist heterocyclic compounds
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
EP2641900A1 (en)	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014044288A1 (en) *	2012-09-21	2014-03-27	Crystal Pharma Sa	Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3345904B1 (en)	2012-12-06	2020-07-29	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko)	2012-12-06	2020-09-17	키에시 파르마슈티시 엣스. 피. 에이.	무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
AU2013360866A1 (en)	2012-12-18	2015-07-02	Almirall, S.A.	New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
EP2956455B1 (en)	2013-02-13	2017-05-17	Novartis AG	Ip receptor agonist heterocyclic compounds
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
CZ306252B6 (cs) *	2013-03-15	2016-10-26	Zentiva, K.S.	Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP3022201A1 (en)	2013-07-18	2016-05-25	Novartis AG	Autotaxin inhibitors
PT3022202T (pt)	2013-07-18	2019-09-03	Novartis Ag	Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
EP3134397A1 (en)	2014-04-24	2017-03-01	Novartis AG	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en)	2014-04-24	2018-10-30	Novartis Ag	Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PL3134395T3 (pl)	2014-04-24	2018-07-31	Novartis Ag	Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017001907A1 (en) *	2015-06-29	2017-01-05	Teva Pharmaceuticals International Gmbh	Biocatalytic processes for the preparation of vilanterol
WO2017093208A1 (en)	2015-12-03	2017-06-08	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN107849019A (zh) *	2016-01-22	2018-03-27	四川海思科制药有限公司	一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
EP3484879B1 (en)	2016-07-13	2020-12-30	Chiesi Farmaceutici S.p.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN106706868B (zh) *	2016-11-15	2018-12-04	河南省农业科学院	人工表达HSP27蛋白在检测β2-肾上腺素受体激动剂类药物残留方面的应用
JP6963616B2 (ja) *	2016-12-14	2021-11-10	ベイジンショウバイファーマシューティカルカンパニー，リミティッド	４級アンモニウム塩構造を有する二官能性化合物
CN106632257B (zh) *	2016-12-15	2019-02-12	上海市奉贤区中心医院	Gsk961081及其中间体的合成方法
EP3787637A4 (en)	2018-02-07	2021-12-08	Duke University	SYSTEM AND METHOD FOR PHOSPHORYLATION OF HOMOGENEOUS GPCR AND IDENTIFICATION OF POSITIVE ALLOSTERIC MODULATORS OF BETA-2 ADRENERGIC RECEPTOR
WO2020047225A1 (en)	2018-08-30	2020-03-05	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
EP3980121A1 (en)	2019-06-10	2022-04-13	Novartis AG	Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PH12022550468A1 (en)	2019-08-28	2023-03-06	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2022175982A1 (en) *	2021-02-19	2022-08-25	Gbr Laboratories Private Limited	A process for preparing batefenterol and intermediates thereof
CN114409890A (zh) *	2022-02-28	2022-04-29	中国科学院长春应用化学研究所	一种氨基功能化的聚乙二醇衍生物及其制备方法
CN118420569B (zh) *	2024-04-24	2025-02-11	渭南瑞联制药有限责任公司	一种(s)-氧杂环丁烷-2-甲胺的合成方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022776A (en) *	1974-01-31	1977-05-10	Otsuka Pharmaceutical Company Limited	5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
BR8007911A (pt)	1979-12-06	1981-06-16	Glaxo Group Ltd	Inalador aperfeicoado
ATE23272T1 (de)	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
DE3134590A1 (de)	1981-09-01	1983-03-10	Boehringer Ingelheim KG, 6507 Ingelheim	Neue benzo-heterocyclen
US4460581A (en) *	1982-10-12	1984-07-17	Boehringer Ingelheim Kg	(1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) *	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
EP0211595B1 (en)	1985-07-30	1991-11-13	Glaxo Group Limited	Devices for administering medicaments to patients
US4894219A (en) *	1988-03-29	1990-01-16	University Of Florida	Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5225183A (en)	1988-12-06	1993-07-06	Riker Laboratories, Inc.	Medicinal aerosol formulations
DK443489D0 (da)	1989-09-08	1989-09-08	Ferrosan As	Substituerede urinstofforbindelser, deres fremstilling og anvendelse
HU213221B (en)	1990-03-02	1997-03-28	Glaxo Group Ltd	Inhalation device and medicine packet for device
US6006745A (en)	1990-12-21	1999-12-28	Minnesota Mining And Manufacturing Company	Device for delivering an aerosol
US5874063A (en)	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
AU2178392A (en)	1991-06-12	1993-01-12	Minnesota Mining And Manufacturing Company	Albuterol sulfate suspension aerosol formulations
US5337740A (en)	1991-08-01	1994-08-16	New England Pharmaceuticals, Inc.	Inhalation devices
DK0617610T3 (da)	1991-12-18	1997-10-06	Minnesota Mining & Mfg	Suspensionsaerosolformuleringer.
TW297025B (pl) *	1992-02-14	1997-02-01	Squibb & Sons Inc
PT640081E (pt)	1992-03-31	2000-05-31	Glaxo Group Ltd	Derivados de fenil-carbamatos e fenil-ureias substituidos sua preparacao e sua utilizacao como antagonistas 5-ht4
US5239993A (en)	1992-08-26	1993-08-31	Glaxo Inc.	Dosage inhalator providing optimized compound inhalation trajectory
US5497763A (en)	1993-05-21	1996-03-12	Aradigm Corporation	Disposable package for intrapulmonary delivery of aerosolized formulations
CA2123728A1 (en) *	1993-05-21	1994-11-22	Noriyoshi Sueda	Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en)	1993-09-02	1995-03-09	Yamanouchi Pharmaceutical Co., Ltd.	Carbamate derivative and medicine containing the same
US5415162A (en)	1994-01-18	1995-05-16	Glaxo Inc.	Multi-dose dry powder inhalation device
WO1995021820A1 (en)	1994-02-10	1995-08-17	Yamanouchi Pharmaceutical Co., Ltd.	Novel carbamate derivative and medicinal composition containing the same
US5495054A (en)	1994-05-31	1996-02-27	Sepracor, Inc.	Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US5983956A (en)	1994-10-03	1999-11-16	Astra Aktiebolag	Formulation for inhalation
SE9501384D0 (sv)	1995-04-13	1995-04-13	Astra Ab	Process for the preparation of respirable particles
JPH11509434A (ja)	1995-04-14	1999-08-24	グラクソ、ウェルカム、インコーポレーテッド	サルメテロール用計量投与用吸入器
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE69615214T2 (de)	1995-10-13	2002-06-27	Banyu Pharmaceutical Co., Ltd.	Substituierte heteroaromatische derivate
PE92198A1 (es)	1996-08-01	1999-01-09	Banyu Pharma Co Ltd	Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) *	1996-11-11	2000-03-21	Sepracor Inc.	Formoterol process
AU9281298A (en)	1997-10-01	1999-04-23	Kyowa Hakko Kogyo Co. Ltd.	Benzodioxole derivatives
EP1047691A1 (en)	1997-12-12	2000-11-02	Smithkline Beecham Plc	Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DK1070056T3 (da)	1998-03-14	2004-11-08	Altana Pharma Ag	Phthalazinon-PDE III/IV-inhibitorer
DK1073417T3 (da)	1998-04-18	2003-03-24	Glaxo Group Ltd	Farmaceutisk aerosolformulering
GB9808802D0 (en)	1998-04-24	1998-06-24	Glaxo Group Ltd	Pharmaceutical formulations
GB9812088D0 (en)	1998-06-05	1998-08-05	Celltech Therapeutics Ltd	Chemical compounds
JP2002517464A (ja)	1998-06-08	2002-06-18	アドバンスドメディスンインコーポレーテッド	ムスカリン性レセプターアンタゴニスト
US6713651B1 (en) *	1999-06-07	2004-03-30	Theravance, Inc.	β2-adrenergic receptor agonists
US6541669B1 (en) *	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
SE9804000D0 (sv)	1998-11-23	1998-11-23	Astra Ab	New composition of matter
CA2347912A1 (en) *	1998-12-18	2000-06-22	Soo S. Ko	Heterocyclic piperidines as modulators of chemokine receptor activity
US6693202B1 (en) *	1999-02-16	2004-02-17	Theravance, Inc.	Muscarinic receptor antagonists
DE19921693A1 (de)	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
ES2193069T3 (es)	1999-04-14	2003-11-01	Glaxo Group Ltd	Formulacion farmaceutica en aerosol.
US6593497B1 (en) *	1999-06-02	2003-07-15	Theravance, Inc.	β2-adrenergic receptor agonists
UA73543C2 (uk) *	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
MXPA02005596A (es) *	1999-12-07	2004-09-10	Theravance Inc	Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73965C2 (en) *	1999-12-08	2005-10-17	Theravance Inc	b2 ADRENERGIC RECEPTOR ANTAGONISTS
CZ20023997A3 (cs)	2000-06-05	2003-05-14	Altana Pharma Ag	Pyridazinonové deriváty
HUP0303529A3 (en)	2000-12-22	2008-03-28	Almirall Ag	New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
JP2004526720A (ja)	2001-03-08	2004-09-02	グラクソ　グループ　リミテッド	βアドレナリン受容体のアゴニスト
WO2002076933A1 (en)	2001-03-22	2002-10-03	Glaxo Group Limited	Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) *	2001-06-23	2003-01-23	Boehringer Ingelheim Pharma Kg	Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
ATE417606T1 (de)	2001-09-14	2009-01-15	Glaxo Group Ltd	Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
US6653323B2 (en) *	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) *	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
PT1497289E (pt)	2002-04-12	2005-11-30	Boehringer Ingelheim Pharma	Farmaco contendo betamimeticos e um novo anticolinergico
EP1507754A1 (en) *	2002-05-28	2005-02-23	Theravance, Inc.	Alkoxy aryl beta-2 adrenergic receptor agonists
US6711451B2 (en) *	2002-07-02	2004-03-23	3D Systems, Inc.	Power management in selective deposition modeling
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
AR040779A1 (es)	2002-08-06	2005-04-20	Glaxo Group Ltd	Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en)	2003-04-01	2004-10-21	Theravance, Inc.	Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) *	2003-05-28	2009-07-15	Theravance Inc	Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
TW200510298A (en) *	2003-06-13	2005-03-16	Theravance Inc	Substituted pyrrolidine and related compounds
JP2007524641A (ja) *	2003-07-11	2007-08-30	セラヴァンス，インコーポレーテッド	置換４−アミノ−１−ベンジルピペリジン化合物
ES2329586T3 (es) *	2003-11-21	2009-11-27	Theravance, Inc.	Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) *	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
US7071224B2 (en) *	2004-03-11	2006-07-04	Theravance, Inc.	Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) *	2004-03-11	2007-08-28	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
EP1723109A1 (en) *	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) *	2004-03-11	2007-10-11	セラヴァンス，インコーポレーテッド	ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
EP1723110A1 (en) *	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) *	2004-03-11	2005-09-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) *	2004-03-11	2005-12-01	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
WO2006023457A1 (en) *	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) *	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound

2004
- 2004-02-11 PE PE2004000152A patent/PE20040950A1/es active IP Right Grant
- 2004-02-13 AU AU2004213411A patent/AU2004213411B2/en not_active Ceased
- 2004-02-13 MX MXPA05008528A patent/MXPA05008528A/es active IP Right Grant
- 2004-02-13 EP EP15196303.0A patent/EP3012254B1/en not_active Expired - Lifetime
- 2004-02-13 MY MYPI20040480A patent/MY148487A/en unknown
- 2004-02-13 WO PCT/US2004/004273 patent/WO2004074812A2/en not_active Ceased
- 2004-02-13 JP JP2006503604A patent/JP4555283B2/ja not_active Expired - Fee Related
- 2004-02-13 DK DK04711253.7T patent/DK1615889T3/da active
- 2004-02-13 WO PCT/US2004/004224 patent/WO2004074276A1/en not_active Ceased
- 2004-02-13 US US10/779,157 patent/US7141671B2/en not_active Expired - Lifetime
- 2004-02-13 KR KR1020057014929A patent/KR101223991B1/ko not_active Expired - Fee Related
- 2004-02-13 WO PCT/US2004/004449 patent/WO2004074246A2/en not_active Ceased
- 2004-02-13 JP JP2006503544A patent/JP2006517971A/ja not_active Withdrawn
- 2004-02-13 PT PT04711253T patent/PT1615889E/pt unknown
- 2004-02-13 EP EP04711117A patent/EP1594860A2/en not_active Withdrawn
- 2004-02-13 EP EP10173127.1A patent/EP2246345B1/en not_active Expired - Lifetime
- 2004-02-13 KR KR1020117010078A patent/KR101224497B1/ko not_active Expired - Fee Related
- 2004-02-13 TW TW093103510A patent/TWI331995B/zh not_active IP Right Cessation
- 2004-02-13 US US10/778,290 patent/US20040209915A1/en not_active Abandoned
- 2004-02-13 AR ARP040100450A patent/AR043176A1/es active IP Right Grant
- 2004-02-13 HU HUE10173127A patent/HUE027380T2/en unknown
- 2004-02-13 JP JP2006503553A patent/JP2006518739A/ja active Pending
- 2004-02-13 SI SI200431566T patent/SI1615889T1/sl unknown
- 2004-02-13 US US10/778,649 patent/US20040209860A1/en not_active Abandoned
- 2004-02-13 RU RU2005128557/04A patent/RU2330841C2/ru active
- 2004-02-13 KR KR1020117027619A patent/KR20110132634A/ko not_active Withdrawn
- 2004-02-13 EP EP04711253A patent/EP1615889B1/en not_active Expired - Lifetime
- 2004-02-13 AT AT04711253T patent/ATE482934T1/de active
- 2004-02-13 DE DE602004029347T patent/DE602004029347D1/de not_active Expired - Lifetime
- 2004-02-13 CA CA2515777A patent/CA2515777C/en not_active Expired - Lifetime
- 2004-02-13 PL PL378025A patent/PL216397B1/pl unknown
- 2004-02-13 NZ NZ541579A patent/NZ541579A/en not_active IP Right Cessation
- 2004-02-13 EP EP04711137A patent/EP1592685A1/en not_active Withdrawn
- 2004-02-13 BR BRPI0407508A patent/BRPI0407508B8/pt not_active IP Right Cessation
- 2004-02-13 DK DK10173127.1T patent/DK2246345T3/en active
- 2004-02-13 ES ES10173127.1T patent/ES2566155T3/es not_active Expired - Lifetime
- 2004-02-13 ES ES15196303.0T patent/ES2636480T3/es not_active Expired - Lifetime
- 2004-02-13 SI SI200432320A patent/SI2246345T1/sl unknown
2005
- 2005-07-27 IL IL169922A patent/IL169922A/en active IP Right Grant
- 2005-07-28 IS IS7964A patent/IS2847B/is unknown
- 2005-09-09 NO NO20054206A patent/NO331947B1/no not_active IP Right Cessation
2006
- 2006-06-07 US US11/448,294 patent/US7355046B2/en not_active Expired - Lifetime
- 2006-06-07 US US11/448,293 patent/US7345175B2/en not_active Expired - Lifetime
- 2006-06-07 US US11/448,317 patent/US7879879B2/en active Active
- 2006-06-07 US US11/449,004 patent/US7521561B2/en not_active Expired - Lifetime
- 2006-10-18 US US11/582,885 patent/US7524959B2/en not_active Expired - Lifetime
- 2006-11-27 US US11/604,607 patent/US7514558B2/en not_active Expired - Lifetime
2007
- 2007-02-09 JP JP2007031325A patent/JP2007119496A/ja not_active Withdrawn
- 2007-04-19 US US11/788,343 patent/US20070208176A1/en not_active Abandoned
- 2007-07-13 US US11/879,004 patent/US7829583B2/en not_active Expired - Lifetime
- 2007-08-01 US US11/888,526 patent/US7507751B2/en not_active Expired - Lifetime
2010
- 2010-04-14 JP JP2010093582A patent/JP5247757B2/ja not_active Expired - Fee Related
- 2010-09-08 AU AU2010219338A patent/AU2010219338B2/en not_active Ceased
- 2010-11-30 CY CY20101101092T patent/CY1111276T1/el unknown
2011
- 2011-01-21 US US13/011,100 patent/US8242135B2/en not_active Expired - Fee Related
- 2011-04-06 HK HK16104933.4A patent/HK1216892A1/en unknown
- 2011-08-05 JP JP2011172162A patent/JP5436503B2/ja not_active Expired - Fee Related
2012
- 2012-02-15 NO NO20120150A patent/NO333394B1/no not_active IP Right Cessation
- 2012-07-10 US US13/545,523 patent/US8618131B2/en not_active Expired - Fee Related
2013
- 2013-11-22 US US14/087,404 patent/US8969571B2/en not_active Expired - Lifetime
2016
- 2016-04-28 CY CY20161100361T patent/CY1117459T1/el unknown

Also Published As

Publication number	Publication date
US20040167167A1 (en)	2004-08-26
EP3012254A1 (en)	2016-04-27
EP1592685A1 (en)	2005-11-09
US7829583B2 (en)	2010-11-09
EP2246345A1 (en)	2010-11-03
CA2515777A1 (en)	2004-09-02
NO20120150L (no)	2005-10-19
IL169922A (en)	2013-08-29
NZ541579A (en)	2008-08-29
US7345175B2 (en)	2008-03-18
US20070276003A1 (en)	2007-11-29
DK1615889T3 (da)	2010-12-20
IS2847B (is)	2013-09-15
JP2007119496A (ja)	2007-05-17
US20040209860A1 (en)	2004-10-21
ES2566155T3 (es)	2016-04-11
DE602004029347D1 (de)	2010-11-11
HUE027380T2 (en)	2016-09-28
US7524959B2 (en)	2009-04-28
WO2004074812A3 (en)	2004-11-04
NO20054206L (no)	2005-10-19
RU2330841C2 (ru)	2008-08-10
US20130150404A1 (en)	2013-06-13
ES2636480T3 (es)	2017-10-05
JP2010159291A (ja)	2010-07-22
KR101224497B1 (ko)	2013-01-23
PT1615889E (pt)	2010-12-09
US7141671B2 (en)	2006-11-28
CA2515777C (en)	2013-01-22
US20070037984A1 (en)	2007-02-15
EP1615889A2 (en)	2006-01-18
JP2006517978A (ja)	2006-08-03
AU2004213411A1 (en)	2004-09-02
IS7964A (is)	2005-07-28
NO331947B1 (no)	2012-05-07
US20110312994A1 (en)	2011-12-22
PL216397B1 (pl)	2014-03-31
TWI331995B (en)	2010-10-21
SI2246345T1 (sl)	2016-06-30
AR043176A1 (es)	2005-07-20
AU2004213411B2 (en)	2010-06-24
US7521561B2 (en)	2009-04-21
JP2006518739A (ja)	2006-08-17
JP5436503B2 (ja)	2014-03-05
ATE482934T1 (de)	2010-10-15
US7507751B2 (en)	2009-03-24
RU2005128557A (ru)	2006-03-20
US20060223860A1 (en)	2006-10-05
BRPI0407508A (pt)	2006-02-14
WO2004074246A3 (en)	2004-11-18
US20060223859A1 (en)	2006-10-05
AU2010219338B2 (en)	2012-07-12
KR20050102114A (ko)	2005-10-25
MY148487A (en)	2013-04-30
KR20110053393A (ko)	2011-05-20
US7514558B2 (en)	2009-04-07
DK2246345T3 (en)	2016-05-02
WO2004074812A2 (en)	2004-09-02
JP2006517971A (ja)	2006-08-03
US20070088054A1 (en)	2007-04-19
HK1086266A1 (en)	2006-09-15
US7355046B2 (en)	2008-04-08
KR20110132634A (ko)	2011-12-08
US20060223858A1 (en)	2006-10-05
MXPA05008528A (es)	2005-10-20
CY1111276T1 (el)	2015-08-05
NO333394B1 (no)	2013-05-27
EP2246345B1 (en)	2016-02-10
NO20054206D0 (no)	2005-09-09
US20060229334A1 (en)	2006-10-12
US8969571B2 (en)	2015-03-03
US20040209915A1 (en)	2004-10-21
BRPI0407508B8 (pt)	2021-05-25
SI1615889T1 (sl)	2011-01-31
EP3012254B1 (en)	2017-05-17
JP2011225617A (ja)	2011-11-10
EP1615889B1 (en)	2010-09-29
JP5247757B2 (ja)	2013-07-24
WO2004074246A2 (en)	2004-09-02
TW200424173A (en)	2004-11-16
WO2004074276B1 (en)	2004-10-07
US20080015220A1 (en)	2008-01-17
AU2010219338A1 (en)	2010-09-30
JP4555283B2 (ja)	2010-09-29
PE20040950A1 (es)	2005-01-01
US7879879B2 (en)	2011-02-01
US20070208176A1 (en)	2007-09-06
WO2004074276A1 (en)	2004-09-02
US20140235864A1 (en)	2014-08-21
US8618131B2 (en)	2013-12-31
HK1216892A1 (en)	2016-12-09
BRPI0407508B1 (pt)	2015-12-01
KR101223991B1 (ko)	2013-01-21
HK1149548A1 (en)	2011-10-07
CY1117459T1 (el)	2017-04-26
EP1594860A2 (en)	2005-11-16
US8242135B2 (en)	2012-08-14

Publication	Publication Date	Title
SI1594840T1 (sl)	2006-12-31	Derivati piperidin-benzensulfonamida
ZA200603879B (en)	2010-01-27	Substituted indazole-O-glucosides
IL175490A0 (en)	2011-08-01	Substituted indazole-o-glucosides
IL169905A0 (en)	2007-07-04	Novel 2-pyridinecarboxamide derivatives
GB0317665D0 (en)	2003-09-03	Qinazoline derivatives
EP1680131A4 (en)	2009-05-27	SUBSTITUTED INDOLE-O-GLUCOSIDES
DE602004020356D1 (en)	2009-05-14	Phenoxyessigsäurederivate
ZA200603880B (en)	2010-01-27	Substituted indole-O-glucosides
SI1682493T1 (sl)	2009-06-30	Amidoacetonitrilni derivati
PL1606277T3 (pl)	2008-10-31	Pochodne imidazol-4-iloetynylo-pirydyny
TWI368482B (en)	2012-07-21	New 2-pyridinylethylbenzamide derivatives
IL175189A0 (en)	2006-09-05	N-thiazol-2-yl-benzamide derivatives
DE502004004146D1 (en)	2007-08-02	Pyrazolverbindungen
PL1706373T3 (pl)	2010-05-31	Pochodne amidoacetonitrylu
ZA200600430B (en)	2009-08-26	Substituted spirobenzazepines
DE502004012153D1 (en)	2011-03-10	Rotorspinnmaschine
GB0312368D0 (en)	2003-07-02	Novel ureido- and amido-pyrazolone derivatives
GB0319793D0 (en)	2003-09-24	Pyridinylmorpholine derivatives
AU155419S (en)	2004-05-13	Trivette
EP1698434A4 (en)	2008-10-15	SANDERS
TWI341309B (en)	2011-05-01	Heteroarylcarbamoylbenzene derivatives
AU2833P (en)	2005-08-22	Baltinrose Gaura lindheimeri
AU2003280822A8 (en)	2005-06-06	Beauveriolide derivatives
GB0319148D0 (en)	2003-09-17	Azaquinazoline derivatives
SI1654253T1 (sl)	2007-04-30	Substituirani 3-pirolidin-indolni derivati